FindTrial
Sign In

A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Lavandula Angustifolia Containing Nasal Spray Medical Device in Preventing Deterioration of COVID-19 in Symptomatic Patients

A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Lavandula Angustifolia Containing Nasal Spray Medical Device in Preventing Deterioration of COVID-19 in Symptomatic Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04974190
Enrollment
550
Registered
2021-07-23
Start date
2021-08-31
Completion date
2022-02-28
Last updated
2021-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Infection

Brief summary

A Nasal Spray device containing Dead Sea minerals and plant extracts, used to shorten duration and mitigate effects of Covid-19 infection in mild to moderate adult patients

Detailed description

A Nasal Spray device containing Dead Sea minerals and plant extracts, designed to incur a PPAR-alpha agonistic effect, used to shorten duration and mitigate effects of Covid-19 infection in mild to moderate adult patients

Interventions

DEVICENasal Spray Device

A Nasal Spray apparatus containing a liquid

Sponsors

Sherutei Briut Clalit
CollaboratorOTHER
The Grasses of Eden Ltd
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Intervention model description

A control group is allocated a placebo solution

Eligibility

Sex/Gender
ALL
Age
16 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

Having tested positive to Covid-19 on PCR test -

Exclusion criteria

Pregnancy Low blood pressure On immune system suppressing medications \-

Design outcomes

Primary

MeasureTime frameDescription
Covid-19 infection self-testing on days 2, 4 following testing positive on PCR testFirst 7 days after testing positive on PCR testTesting using a self testing kit of the Quidel QuickView type
Symptoms monitoringFirst 7 days after testing positive on PCR testMonitoring any disease symptoms reported by patient

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026